Guidance covering various aspects of pharmacovigilance for authorised and unauthorised medicinal products (Specials and the Early Access to Medicines Scheme (EAMS)).
Similar Posts
Class 4 Medicines Defect Notification: Special Concept Development UK Limited, Baclofen 10mg Tablets, EL(25)A/51
Special Concept Development UK Limited has informed the MHRA that the Patient Information Leaflet (PIL) for the batches listed in this notification do not contain the correct safety information.
MHRA patient safety essay competition 2025
The MHRA is inviting the next generation of doctors to explore how genetics could improve prescribing and patient safety in the UK.
Patient and family experiences inform antidepressant safety information review
An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients
Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices
This consultation invites views on proposals for recognising CE marked medical devices in Great Britain.
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.